GlassScriptPhysician profile
David Scott Mccaul
NPI 1902917784
$2,918.36
in general payments reported to CMS, 2019-2025
29 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $230 · 2021: $219 · 2022: $171 · 2023: $311 · 2024: $441 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.15 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $459.04 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.67 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $299.72 | 2019-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $219.55 | 2019-2025 | Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $200.14 | 2019-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $192.69 | 2019-2024 | Winrevair |
| Mylan Specialty L.P. | $160.73 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $156.94 | 2022-2025 | Prolastin-C Liquid |
| Philips North America LLC | $146.09 | 2022-2025 | (O58) Sleep Respiratory Care Und, Encore |
| Watermark Medical, INC. | $91.63 | 2021 | |
| Baxter Healthcare | $69.80 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $56.94 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $50.91 | 2019-2020 | |
| Verona Pharma, INC. | $45.18 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $39.00 | 2024 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $35.58 | 2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $30.12 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $28.92 | 2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $25.86 | 2023 | |
| Gilead Sciences, INC. | $22.75 | 2025 | Veklury |
| Genentech USA, INC. | $22.21 | 2019 | |
| Viatris Specialty LLC | $21.54 | 2025 | Yupelri |
| Advanced Respiratory, INC | $20.83 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.98 | 2020 | |
| Sanofi Pasteur INC. | $18.81 | 2019 | |
| Resmed Corp | $17.64 | 2020 | |
| Cook Medical LLC | $17.57 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.